Biogen (NASDAQ: BIIB) reported Q3 EPS of $5.19, $0.22 better than the analyst estimate of $4.97. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.

Eloctate revenue $131.8 million, est. $131.2 million.
Alprolix revenue $85.2 million, est. $86.2 million.

For earnings history and earnings-related data on Biogen (BIIB) click here.